Golgi Neurosciences is pleased to announce the adoption of Collaborative Drug Discovery’s CDD Vault as unique platform for managing its drug discovery data, which will enable a more efficient research and development.
Golgi Neurosciences is pleased to announce the adoption of Collaborative Drug Discovery’s CDD Vault as unique platform for managing its drug discovery data, which will enable a more efficient research and development.
Golgi Neurosciences is pleased to announce the adoption of Collaborative Drug Discovery’s CDD Vault as unique platform for managing its drug discovery data, which will enable a more efficient research and development.
Golgi Neurosciences and Breye Therapeutics are thrilled to announce a collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders.
Golgi Neurosciences Srl is proud to announce its launch as an independent and unique incubator. The company is dedicated to the discovery and development of innovative small molecule treatments to combat neurodegenerative diseases.
Golgi Neurosciences is a company-creator boutique with one ambitious mission: setting the ground to create therapies for the treatment of devasting neurodegenerative diseases by applying rigorously “Grounded Objectives Leading to a Great Impact (GOLGI)”.
Golgi Neurosciences S.r.l.
Kunzi Campus - via Ariosto, 19
20091 Bresso (Milan, Italy)
Share capital: 430.815 euro
C.F./P.IVA/VAT: 12596130968
Numero REA: MI-2671780
Copyright © 2026 Golgi Neurosciences. All rights reserved | Privacy Policy | Cookie Policy | Disclaimer